MedPath

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Public
Established
2004-01-01
Employees
4
Market Cap
-
Website
http://www.provectusbio.com

Clinical Trials

6

Active:4
Completed:0

Trial Phases

2 Phases

Phase 1:4
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (80.0%)
Phase 3
1 (20.0%)

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Phase 1
Active, not recruiting
Conditions
Neuroendocrine Tumors Metastatic to the Liver
Interventions
First Posted Date
2016-02-26
Last Posted Date
2023-02-08
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Target Recruit Count
12
Registration Number
NCT02693067
Locations
🇦🇺

The Queen Elizabeth Hospital, Woodville, South Australia, Australia

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Phase 1
Active, not recruiting
Conditions
Melanoma
Interventions
First Posted Date
2015-09-23
Last Posted Date
2023-11-21
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Target Recruit Count
50
Registration Number
NCT02557321
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

and more 2 locations

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Phase 3
Terminated
Conditions
Cutaneous Melanoma
Interventions
Drug: PV-10 (10% rose bengal disodium)
Drug: Dacarbazine, temozolomide or talimogene laherparepvec
First Posted Date
2014-11-11
Last Posted Date
2022-01-19
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT02288897
Locations
🇺🇸

Sharp Memorial Hospital - Clinical Oncology Research, San Diego, California, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

🇺🇸

Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 20 locations

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Conditions
Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory
Approved Alternative Therapy
First Posted Date
2010-12-15
Last Posted Date
2016-07-11
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Registration Number
NCT01260779
Locations
🇺🇸

University of Louisville, Louisville, Kentucky, United States

🇺🇸

St Luke's University Health Network, Bethlehem, Pennsylvania, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Phase 1
Active, not recruiting
Conditions
Metastatic Ocular Melanoma
Metastatic Uveal Melanoma
Hepatocellular Carcinoma
Metastatic Lung Cancer
Metastatic Colon Cancer
Cancer Metastatic to the Liver
Metastatic Melanoma
Metastatic Colorectal Cancer
Metastatic Pancreatic Cancer
Metastatic Breast Cancer
Interventions
Drug: PV-10 (10% rose bengal disodium)
First Posted Date
2009-09-30
Last Posted Date
2022-11-02
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Target Recruit Count
78
Registration Number
NCT00986661
Locations
🇺🇸

Sharp Memorial Hospital, San Diego, California, United States

🇺🇸

Florida Hospital Tampa, Tampa, Florida, United States

🇺🇸

St Luke's University Health Network, Bethlehem, Pennsylvania, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.